What is Epipole?
Founded in 2011 by Dr. Craig Robertson, Epipole operates at the intersection of advanced mathematical problem solving and clinical vision systems. As an ISO13485 certified entity, the company maintains rigorous quality management standards essential for the design and manufacture of medical-grade retinal imaging devices. The organization is distinguished by a leadership team possessing over 90 years of collective experience in bringing complex medical technologies to market, having successfully launched numerous businesses and over 35 distinct products. Their core competency lies in the development of non-invasive, high-resolution imaging systems that provide clinicians with actionable diagnostic data, effectively bridging the gap between complex algorithm development and practical, patient-centric healthcare applications.
How much funding has Epipole raised?
Epipole has raised a total of $3.6M across 2 funding rounds:
Other Financing Round
$1.9M
Unspecified
$1.7M
Other Financing Round (2020): $1.9M with participation from Greenwood Way Capital Limited
Unspecified (2022): $1.7M led by Scottish Enterprise and Greenwood Way Capital
Key Investors in Epipole
Scottish Enterprise
A national economic development agency and non-departmental public body of the Scottish Government that provides strategic support and funding to high-growth potential businesses.
Greenwood Way Capital
An investment syndicate that facilitates co-investment opportunities for funds and individuals into early-stage UK companies with disruptive technologies.
Greenwood Way Capital Limited
An investment entity focused on providing early-stage capital to innovative UK-based enterprises, often participating in syndicates to support long-term growth.
What's next for Epipole?
Looking ahead, the strategic deployment of this recent financing will likely focus on scaling production capacity and navigating the regulatory pathways required for broader market penetration. Given the company's established track record in retinal imaging, the focus will shift toward optimizing supply chain resilience and potentially expanding the diagnostic capabilities of their existing hardware suite. As the company transitions from a development-heavy phase to a more aggressive commercialization strategy, the support from institutional backers will be instrumental in maintaining their competitive edge in the highly regulated medical device landscape. Future growth will likely be defined by the successful integration of their proprietary algorithms into next-generation screening platforms, further solidifying their position as a leader in the Scottish health-tech ecosystem.
See full Epipole company page
